![]() Of these variants 26 are known to have decreased or no function but current testing typically uses a targeted approach by which only a hand full of the more common variants (in populations of European background) are tested. There are over 450 known genetic variants in DPYD according to the Pharmacogene Variation Consortium (PharmVar, ). Second, DPYD testing needs to be comprehensive to reduce false negatives. Unfortunately, clinical practice guidelines in Canada have yet to recommend routine testing, despite the known link between DPYD genetic variants and toxicity and the availability of recommendations produced by expert consortia for how to use DYPD testing results to inform 5-FU treatment ( ). #GPCPD #mooddisorders #psychedelics #eatingdisorders #pharmacogenomics #psychiatry #ketamineįirst, DPYD pharmacogenomic testing prior to fluorouracil (5-FU) should be standard of care in Canada (and everywhere). Thanks to our sponsors Otsuka Australia Pharmaceutical Pty Ltd who kept us fed while we listened to these engaging presenters. Prof Murray Tucker, clinical director of one of The Geelong Clinic’s eating disorders inpatient programs, on the risk factors and symptoms of eating disorders, treatment options and local care pathways available for patients and their families.Īnd we can’t forgot our MC for the night Prof Ajeet B Singh MD PhD who seems to have missed his calling and ensured the audience had fun, learned something and asked lots of questions! Ranjini Rao, FRCPsych, MSc, FRANZCP, IFAPA, AICGG shared some insights on therapeutic options for treatment-resistant depression including ketamine and psilocybin, as well as the role of pharmacogenetics in medication prescribing. It must’ve been the lure of two great speakers on two interesting and relevant topics - tackling mood disorders and eating disorders in general practice.ĭr. They braved a wet and windy night in Geelong to join us for this GP CPD event. Webinar Replay: PGx Testing Developments and Future Directions - Agena Bioscience If you missed the live session, don't worry! Watch the replay here: #PrecisionMedicine #PGxTesting #Webinar #HealthcareInnovation #Pharmacogenomics #PGx The field of PGx is rapidly advancing and shows great promise for reducing adverse drug events and improving patient safety, particularly in the areas of cardiac, oncology and pain management drug selection, dosing, and treatments. Significant challenges remain that slow the widespread adoption of PGx, including reimbursement and clinician/physician awareness and education as to the benefits of PGx testing.ģ. PGx has made great advancements benefiting healthcare, particularly in the areas of chemotherapy drug toxicity profiling (DPYD) and psychotropics (anxiety and depression).Ģ. This panel delved deep into the evolving landscape of Pharmacogenomics (PGx) testing and its pivotal role in shaping the future of precision medicine. Bronwyn Ramey, Director of Precision Medicine at LetsGetChecked and Glenn Sawyer, Associate Director for Clinical Genetics at Agena Bioscience. We recently co-hosted an enlightening panel discussion with GenomeWeb, titled "PGx Testing Developments and Future Directions," featuring industry luminaries Dr. Paper □ #ECT #Depression #neuroscience #psychscene #hippocampus Differences between groups in medications used. ![]() ![]() Specific Histopathological findings revealed:ġ️⃣ No indications of hippocampal cell loss or overt changes.Ģ️⃣ Inflammatory markers for astrocytes and microglia showed no differences.ģ️⃣ A higher percentage of Doublecortin-positive cells, indicating enhanced cellular plasticity.Ĥ️⃣ Increased Stathmin 1 positivity in the subgranular zone, signaling heightened neuroplasticity.ġ. □□ No major cell loss, cytoarchitectural changes, or classic neuropathology were observed "The first post-mortem observations suggest that ECT has no damaging effects but may rather have induced neuroplasticity in the DG (dentate gyrus) of depressed patients."Įxamination of the post-mortem hippocampus of bipolar or unipolar depressed patients who underwent ECT in the 5 years preceding their death □ First Post-Mortem Insights on ECT's Impact on the Human Brain □□
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |